New drug emrusolmin tested for Long-Term safety in rare brain disease

NCT ID NCT07197866

Recruiting now Disease control Sponsor: Teva Branded Pharmaceutical Products R&D LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing the long-term safety of an oral drug called Emrusolmin (TEV-56286) in 200 adults with multiple system atrophy (MSA), a rare and serious brain disorder. Participants who completed a prior trial will take the drug for about 100 weeks. The main goal is to see how many people have side effects or drop out due to side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Emrusolmin (TEV-56286) taken orally

What this could lead to

If successful, this study could show that Emrusolmin is safe enough to use long-term for multiple system atrophy, potentially slowing disease progression.

What could go wrong

This is an early-phase, open-label extension trial focused on safety, not effectiveness. It is small (200 participants) and may not prove the drug works or is safe for everyone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple system atrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SYSTEM ATROPHY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Teva Investigational Site 15543
RECRUITING

Spokane, Washington, 99202, United States
Teva Investigational Site 15544
RECRUITING

Boca Raton, Florida, 33486, United States
Teva Investigational Site 15549
RECRUITING

New York, New York, 10016, United States
Teva Investigational Site 15551
RECRUITING

New York, New York, 10032-3726, United States
Teva Investigational Site 15554
RECRUITING

La Jolla, California, 92037, United States
Teva Investigational Site 15555
RECRUITING

Tampa, Florida, 33613, United States
Teva Investigational Site 30295
RECRUITING

Salerno, 84131, Italy
Teva Investigational Site 30296
RECRUITING

Roma, 00163, Italy
Teva Investigational Site 30298
RECRUITING

Milan, 20132, Italy
Teva Investigational Site 30299
RECRUITING

Bologna, 40139, Italy
Teva Investigational Site 31320
RECRUITING

Pamplona, 31008, Spain
Teva Investigational Site 31322
RECRUITING

Seville, 41013, Spain
Teva Investigational Site 31323
RECRUITING

Barcelona, 08035, Spain
Teva Investigational Site 31324
RECRUITING

Barcelona, 08025, Spain
Teva Investigational Site 32818
RECRUITING

Dresden, 01307, Germany
Teva Investigational Site 32822
RECRUITING

Düsseldorf, 40225, Germany
Teva Investigational Site 32824
RECRUITING

Marburg, 35033, Germany
Teva Investigational Site 32825
RECRUITING

Kassel, 34128, Germany
Teva Investigational Site 35290
RECRUITING

Bordeaux, 33400, France
Teva Investigational Site 35291
RECRUITING

Paris, 75651, France
Teva Investigational Site 35292
RECRUITING

Toulouse, 31059, France
Teva Investigational Site 80203
RECRUITING

Haifa, 31999, Israel
Teva Investigational Site 80204
RECRUITING

Tel Aviv, 6423906, Israel
Teva Investigational Site 84135
RECRUITING

Sendai, 982-8555, Japan
Teva Investigational Site 84137
RECRUITING

Niigata, 951-8520, Japan
Teva Investigational Site 84138
RECRUITING

Sagamihara, 252-0392, Japan
Teva Investigational Site 84141
RECRUITING

Sanda-shi, 669-1592, Japan